Publications & Talks
Our Research / Publications & Talks
Neuroscience: Standard model.
Schnabel J. Neuroscience: Standard model. Nature. 2008 Aug 7;454(7205):682-5.
PubMed LinkClinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS.
Hammad M, Silva A, Glass J, Sladky JT, Benatar M. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology. 2007 Dec 11;69(24):2236-42.
PubMed LinkWhat zebras and mice can teach us about familial ALS.
Benatar M. What zebras and mice can teach us about familial ALS. Neuromuscul Disord. 2007 Oct;17(9-10):671-2. Epub 2007 Jul 12.
PubMed LinkDiagnostic accuracy of thoracic paraspinal electromyography in amyotrophic lateral sclerosis.
Makki AA, Benatar M. Diagnostic accuracy of thoracic paraspinal electromyography in amyotrophic lateral sclerosis. J Clin Neurophysiol. 2007 Jun;24(3):298-300.
PubMed LinkLost in translation: treatment trials in the SOD1 mouse and in human ALS.
Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007 Apr;26(1):1-13. Epub 2007 Jan 3.
PubMed LinkThe electromyographic diagnosis of amyotrophic lateral sclerosis: does the evidence support the El Escorial criteria?
Makki AA, Benatar M. The electromyographic diagnosis of amyotrophic lateral sclerosis: does the evidence support the El Escorial criteria? Muscle Nerve. 2007 May;35(5):614-9.
PubMed LinkPreventing familial amyotrophic lateral sclerosis: is a clinical trial feasible?
Benatar M, Polak M, Kaplan S, Glass J. Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible? J Neurol Sci. 2006 Dec 21;251(1-2):3-9. Epub 2006 Sep 26.
PubMed LinkDefining mild cognitive and behavioural impairment in pre-symptomatic ALS/FTD.
McHutchison CA (presenter), Abrahams S, Wuu J, Cosentino S, Benatar M. Defining mild cognitive and behavioural impairment in pre-symptomatic ALS/FTD. ePoster presentation at the 33rd International Symposium on ALS/MND (Virtual), Dec 6-9, 2022.
Mild Motor Impairment and Prodromal Disease Markers.
Benatar M (plenary speaker). Mild Motor Impairment and Prodromal Disease Markers. Platform presentation at the 33rd International Symposium on ALS/MND (Virtual), Dec 6-9, 2022.
Patterns of longitudinal cognitive and behavioural changes in ALS/MND.
McHutchison CA (presenter), Wuu J, Abrahams S, Benatar M. Patterns of longitudinal cognitive and behavioural changes in ALS/MND. ePoster presentation at the 32nd International Symposium on ALS/MND (Virtual), Dec 7-10, 2021.
Genotype phenotype correlation and longitudinal study of hereditary spastic paraplegia and primary lateral sclerosis.
Statland J (presenter), Karanevich A, Wuu J, Swenson A, Barohn RJ, Schule R, Jackson C, Ravits J, Granit V, McCauley J, Zuckner S, Caress J, Trivedi J, Maiser S, Walk D, Pioro E, McMillan C, Elman L, Katz J, Heckmann J, Burns T, So Y, Wu G, Rampersaud E, Rademakers R, van Blitterswijk M, Taylor JP, Benatar M, on behalf of the CReATe Consortium. Genotype phenotype correlation and longitudinal study of hereditary spastic paraplegia and primary lateral sclerosis. Platform presentation at the 30th International Symposium on ALS/MND, Perth, Australia, Dec 4-6, 2019.
Chitotriosidase level and activity rises in the pre- and early symptomatic phases of ALS.
Gray E (presenter), AG Thompson, Wuu J, Pelt J, Talbot K, Benatar M, Turner MR. Chitotriosidase level and activity rises in the pre- and early symptomatic phases of ALS. Platform presentation at the 30th International Symposium on ALS/MND, Perth, Australia, Dec 4-6, 2019.
Baseline and longitudinal volumetric changes associated with presymptomatic C9ORF72 repeat expansion carriers.
McMillan CT (presenter), Wuu J, Cook P, Olm C, Duda J, Gee J, Clayman CE, Elman L, McCluskey L, Irwin DJ, Grossman M, Benatar M. Baseline and longitudinal volumetric changes associated with presymptomatic C9ORF72 repeat expansion carriers. Platform presentation at the 29th International Symposium on ALS/MND, Glassgow, UK, Dec 7-9, 2018.
When does ALS begin? Insights from serum and CSF neurofilament light and heavy.
Benatar M (presenter), Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A. When does ALS begin? Insights from serum and CSF neurofilament light and heavy. Platform presentation at the 29th International Symposium on ALS/MND, Glassgow, UK, Dec 7-9, 2018.
Blood and CSF neurofilament levels as biomarkers of pre-symptomatic disease.
Benatar M (presenter), Wuu J, Lombardi V, Andersen PM, Malaspina A. Blood and CSF neurofilament levels as biomarkers of pre-symptomatic disease. Platform presentation at the 28th International Symposium on ALS/MND, Boston, MA, Dec 8-10, 2017.